INTRODUCTION
============

Approximately 180 million subjects are chronically infected with hepatitis C virus (HCV) worldwide.[@b1-gnl-12-324],[@b2-gnl-12-324] HCV infection is one of the leading causes of chronic liver disease, cirrhosis and hepatocellular carcinoma (HCC).[@b3-gnl-12-324],[@b4-gnl-12-324] HCV is a single-stranded positive RNA virus with seven genotypes. Genotype 1b is the most predominant subtype in Asia, constituting 45% to 55% of all genotypes infecting patients in Korea and Taiwan.[@b5-gnl-12-324],[@b6-gnl-12-324] HCV treatments have evolved rapidly with the development of direct-acting antiviral (DAA) therapies.

In HCV patients, DAA therapies are associated with higher sustained virological response (SVR) rates, reduced treatment durations, and minimal side-effects.[@b7-gnl-12-324] DAAs target principally the HCV nonstructural protein (NS) 3/4A serine protease, the NS5A protein, and the NS5B polymerase.[@b8-gnl-12-324] Daclatasvir (DCV; an NS5A replication complex inhibitor) plus asunaprevir (ASV; an NS3 protease inhibitor) was recently approved in Korea as the first-line DAA treatment for patients chronically infected by HCV genotype 1b.[@b9-gnl-12-324],[@b10-gnl-12-324] In a pooled analysis, a DCV+ASV regimen was effective and well-tolerated in patients with genotype 1b HCV infection, regardless of the presence of cirrhosis.[@b11-gnl-12-324] However, real-world data often differ from those of clinical trials because clinical trials impose several strict inclusion and exclusion criteria. Thus, the collection of real-life data is essential to confirm treatment efficacy and safety in clinical settings.

DCV is a potent pan-genotypic NS5A inhibitor exhibiting antiviral activity across HCV genotypes 1 to 6 *in vitro*. ASV is an NS3 protease inhibitor active against genotypes 1, 4, 5, and 6 *in vitro*.[@b12-gnl-12-324] Dual therapy with DCV+ASV for 24 weeks, without the use of pegylated interferon/ribavirin (PegIFN/RBV), afforded high SVR rates in treatment-naïve patients and those who were ineligible/intolerant (87%) or nonresponsive (81%) to PegIFN/ RBV treatment, provided that they lacked resistance-associated substitutions (RAS).[@b13-gnl-12-324]--[@b15-gnl-12-324] Moreover, DCV+ASV treatment was associated with favorable SVR rates and low levels of adverse events, even in patients with compensated cirrhosis.[@b16-gnl-12-324],[@b17-gnl-12-324]

Viral eradication with IFN-treatment of chronic hepatitis C (CHC) liver fibrosis and reduces the incidences of HCC and liver-related mortality. However, any long-term benefit afforded by viral eradication in HCV-infected patients using IFN-free DAA combination therapy, remains unknown.[@b18-gnl-12-324]--[@b20-gnl-12-324] A recent study founded that improvement of fibrosis was important in CHC patients who treated with sofosbuvir-based regimen.[@b21-gnl-12-324] Although the efficacy and changes in fibrosis have been assessed in clinical trials, few real-world data are available.[@b17-gnl-12-324],[@b22-gnl-12-324] Therefore, we investigated the real-world efficacy, changes in liver stiffness (LS) values and the fibrosis markers, and safety in Korean patients with genotype 1b HCV infection.

MATERIALS AND METHODS
=====================

1. Patients
-----------

A total of 363 patients chronically infected with HCV genotype 1b started 24 weeks treatment with DCV+ASV at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea between August 2015 and January 2017. The doses were DCV 60 mg once daily and ASV 100 mg twice daily. All data were prospectively collected using an established protocol and were followed up for 12 weeks posttreatment.

The inclusion criteria were age ≥20 years, CHC infection with genotype 1b only, and a detectable HCV RNA titer without any RAS ([Fig. 1](#f1-gnl-12-324){ref-type="fig"}). Patients who were nonresponsive to, ineligible for, or intolerant of previous treatment, and those who had relapsed, were included. The exclusion criteria were: (1) hepatic decompensation evident at the time of enrollment or a prior history of decompensation; (2) co-infection with other HCV genotypes or hepatitis B virus; (3) RAS positive at L31 or Y93 (n=36); (4) HCC evident at enrollment (n=53); and (5) loss to follow-up (n=4). Our analyses of efficacy and safety included all patients who received at least one dose of medication.

Written informed consent was obtained from all participants. The study was approved by the Institutional Review Board of Severance Hospital and conformed to the ethical guidelines of the 1975 Helsinki Declaration (IRB Number: 4-2015-0701).

2. Clinical and laboratory evaluation
-------------------------------------

The RASs in the HCV *NS5A* and HCV *NS3* regions were analyzed by Sanger direct-sequencing methods. Clinical data including age, sex, HCV genotype, HCV RNA titer, comorbidities, prior HCV treatment history, and the presence of cirrhosis was assessed at baseline. Clinical assessment was performed at weeks 4, 12, 24 and 36. At each visit, a complete blood cell count, routine blood chemistry tests, and side effects were checked. HCV RNA level were checked at baseline; at 4, 12, and 24 weeks of treatment; and at 12 weeks after the end of treatment (EOT). Serum HCV RNA levels were quantified using a commercial polymerase chain reaction assay (Amplicor HCV; Roche Diagnostics, Seoul, Korea), which has a lower limit of quantification of 15 IU/mL. Serum alanine aminotransferase (ALT) levels were measured using a standard laboratory procedure with the upper limit of normal set to 33 IU/mL in males and 25 IU/mL in females.[@b23-gnl-12-324] During the follow-up period, all patients underwent periodic ultrasonographic and laboratory work-ups, including measurement of α-fetoprotein levels every 3 or 6 months to screen for HCC and other portal hypertension-related complications.

Cirrhosis was diagnosed by liver biopsy (METAVIR score 4 or Ishak score 5, 6), by transient elastography (TE) (LS value \>12.5 kilopascal \[kPa\]), or by measurement of laboratory biomarkers (aspartate aminotransferase to platelet ratio index \[APRI\] \>2.0 and fibrosis-4 \[FIB-4\] score \>3.25.[@b24-gnl-12-324],[@b25-gnl-12-324]

3. Changes in fibrosis assessed by noninvasive markers
------------------------------------------------------

To assess the effect of DCV+ASV treatment, liver fibrosis markers, including the APRI and FIB-4 scores, were measured in all patients at baseline, at the EOT, and at 12 weeks after treatment. An APRI \>2.0 predicts cirrhosis and a FIB-4 \>3.25 predicts advanced fibrosis with a positive predictive value of 65%.[@b26-gnl-12-324],[@b27-gnl-12-324] LS values were assessed by TE both at baseline and SVR12. TE examinations were performed by a single experienced technician (\>20,000 examinations) blinded to patient data. The results were expressed in kilopascal and the median value of successful measurements was selected as representative LS value. The interquartile range (IQR) was defined as an index of the intrinsic variability of LS values corresponding to the interval of LS results containing 50% of the valid measurements between the 25th and 75th percentiles. Only LS values derived from ≥10 valid shots, a success rate ≥60%, and an IQR to median value ratio \<0.3 were considered reliable, and used in statistical analysis.[@b28-gnl-12-324]

4. Assessment of treatment efficacy and safety
----------------------------------------------

The primary endpoint was to evaluate SVR12, defined as undetectable HCV RNA at 12 weeks posttreatment. The second endpoint was to evaluate the changes in liver fibrosis assessed by noninvasive methods before and after DCV+ASV treatment. Treatment responses were defined as follows: relapse; an end of treatment response (ETR), defined as undetectable HCV RNA at the end of treatment; virological breakthrough (VBT); ALT normalization. Adverse events were assessed at each visit.

5. Statistical analysis
-----------------------

Data are expressed as mean±standard deviation (SD), median (with range), or numbers (with percentages), as appropriate. Continuous and categorical variables were compared using Student t-test (or the Mann-Whitney U-test, as appropriate); and the chi-square test (or Fisher exact test, as appropriate), respectively. All statistical analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, NY, USA). A p-value \<0.05 was considered statistically significant.

RESULTS
=======

1. Baseline characteristics
---------------------------

A total of 270 patients followed up for at least 12 weeks after treatment were finally analyzed. Their baseline demographic characteristics are summarized in [Table 1](#t1-gnl-12-324){ref-type="table"}. The mean patient age was 60.7 years (SD, 12.4 years), and females (n=163, 60.4%) predominant. Treatment-naïve patients (n=175, 64.8%) were in the majority. The mean baseline HCV RNA level was 5.9 log~10~ IU/mL (SD, 0.9 log~10~ IU/mL). Of all patients, 56 (20.7%) had cirrhosis. The mean LS value was 13.2 kPa (SD, 12.6 kPa) at baseline.

2. Virological response
-----------------------

Of all patients, 214 patients (79.3%) achieved rapid virologic response defined as undetectable HCV RNA at week 4 of therapy. Two hundred fifty-seven (95.2%) and 251 (93.0%) patients achieved ETR and SVR12, respectively ([Fig. 2A](#f2-gnl-12-324){ref-type="fig"}). The SVR12 rates by prior treatment history were 92.0% (161/175) in treatment-naïve patients and 94.7% (90/95) in those with treatment-experienced (35/37 in non-responders, 30/31 in IFN/ RBV ineligible/intolerant patients, and 25/27 in relapsers) ([Fig. 2B](#f2-gnl-12-324){ref-type="fig"}). The SVR12 rates were higher in patients \<65 years than in those ≥65 years of age (91.9%, 136/148 vs 90.4%, 103/114) ([Fig. 3](#f3-gnl-12-324){ref-type="fig"}). The SVR rate was higher in males (94.4%, 101/107) than females (92.0%, 150/163). SVR12 was achieved both in patients with cirrhosis (87.5%, 49/56) and those without cirrhosis (94.4%, 202/214). When subdivided by the HBV RNA level, 95.2% (119/125) of patients with levels ≥6 log~10~ IU/mL and 91.0% (132/145) of patients with levels \<6 log~10~ IU/mL achieved SVR12. The SVR rate was 92.3% (12/13) in patients with estimated glomerular filtration rates (eGFR) \<50 mL/min/1.73m^2^ and 93.0% (239/257) in those with eGFR ≥50 mL/min/1.73m^2^. In patients with and without diabetes mellitus, 93.5% (29/31) and 92.9% (222/239) of patients achieved SVR12, respectively.

3. Safety and virological failure
---------------------------------

Of patients who had no HCC at baseline and were RAS negative, 16 patients discontinued DCV+ASV treatment prior to 24 weeks because of the development of adverse events (n=5), treatment failure (n=3), and VBT (n=8). One patient discontinued DCV+ASV treatment at week 2 because of gastrointestinal problem. Another developed a skin rash and stopped treatment at week 12. One 63-year-old female patient exhibited mild cre-atinine elevation (from 1.3 to 2.3 mg/dL at week 4) and refused to continue treatment. One 71-year-old female patient stopped treatment at week 4 because of general weakness. One patient discontinued treatment because of uncontrolled ascites at week 20. Among five patients who experienced adverse events, four (80%) had cirrhosis at baseline. Three patients experienced ETR, but recurred at 12 weeks after treatment completion.

DCV+ASV treatment was relatively safe, but one patient experienced drug-drug interactions. She visited the hospital at 24 weeks and we confirmed ETR. However, she was admitted for treatment of severe hepatitis (ALT \>5-fold the upper limit of normal), even though her HCV RNA status was negative. The hepatitis was caused by itraconazole for treatment 1 week in duration; the drug had been prescribed in another clinic to treat vaginitis. After conservative care, she was discharged with improved liver enzyme levels and achieved both an ETR and SVR12. Two patients who achieved SVR12 developed HCC. Both had cirrhosis at baseline and developed HCC approximately 3 months after the end of treatment.

4. Changes in liver fibrosis
----------------------------

The LS values obtained by TE, showed that 49.0% of patients had non-significant fibrosis (grade \<F2), 10.2% mild to significant fibrosis (F2--F3), 10.2% advanced fibrosis (F3--F4) and 30.6% cirrhosis (F4). The FIB-4 score was 4.39±4.66 and the mean APRI 1.13±1.30. All patients exhibited declines in the levels of noninvasive fibrosis markers at SVR12 compared with baseline. Significant decline were also evident in the LS, FIB-4, and APRI values from baseline to SVR12 regardless of cirrhosis status or any prior history of treatment ([Table 2](#t2-gnl-12-324){ref-type="table"}). The overall LS values by TE decreased significantly from 13.2 kPa at baseline to 10.5 kPa at SVR12 (p\<0.001). The overall APRI and FIB-4 scores also decreased significantly ([Fig. 4](#f4-gnl-12-324){ref-type="fig"}). The mean APRI score prior to therapy was 1.40 and that after therapy was 0.60 (p\<0.001). The mean FIB-4 value was 4.57 prior to treatment and 3.03 at 12 weeks posttreatment.

DISCUSSION
==========

We investigated the real-world efficacy of DCV+ASV treatment in patients infected with genotype 1b HCV. DCV+ASV treatment was approved in 2015; and our center has treated the greatest number of patients and has the most extensive collection of long-term data as a single institution in Korea. HCV infection is the second most common cause of chronic liver disease in Korea. HCV prevalence is especially highest among older patients, with rapid disease progression. Of all HCV patients, 2% were ≥70 years of age, and were predominantly female. HCV genotype 1b is the most prevalent subtype in Korea; the prevalence ranges from 45 % to 59 %.[@b29-gnl-12-324],[@b30-gnl-12-324]

ETR was achieved in 95.2% and SVR12 was achieved in 93.0% of all patients. Thus, Korean patients with HCV genotype 1b responded well to treatment regardless of age, sex, cirrhosis status, or HCV RNA levels. In previous studies, DCV+ASV treatment was associated with SVR12 in 90% of treatment-naïve patients, 82% of non-responders, and 82% of ineligible/intolerant patients.[@b11-gnl-12-324] Our results were similar; 92.0% of treatment-naïve patients achieved SVR12. Ninety-four point six percent (35/37) patients of non-responders, 96.0% (30/31) of ineligible/intolerant patients, and 92.6% (25/27) patients of relapsers showed SVR12.

We treated 36 (9.9%, 36/363) patients with *NS5A*-Y93 (n=28) mutations and/or *NS5A*-L31 mutations (n=9). Nineteen patients (52.8%) achieved SVR12. Three patients exhibited VBT and two were non-responders. The SVR rate of RAS-positive patients was slightly higher than that observed in previous clinical trials. We sequenced the viral genomes of five patients who failed DCV+ASV treatment. The well-known Y93H mutation of *NS5A* was observed in four. Substitution mutations at Leu31 (Val or Met) of *NS5A* were also observed in three out of the four Y93H-containing viruses. However, one genome had no substitution mutation at Leu31 and Tyr93 having, rather, a deletion mutation at Pro32.

Overall, 87.5% of cirrhotic patients achieved SVR12 (87.5% in cirrhosis vs 94.4% in non-cirrhosis, p=0.908). This low treatment outcome is probably due to the low number of patients with cirrhosis (n=56) compared with non-cirrhosis (n=214), so a larger number of cirrhotic patients is needed. The concentration of ASV after treatment commencement is associated with a higher rate of ALT elevation in patients with cirrhosis.[@b31-gnl-12-324] However, none of our patients discontinued treatment because the ALT level raised to 5-fold that of the normal upper limit. Of 53 patients with HCC at baseline, 54.7% (29/53) achieved SVR12. Seven HCC patients ceased treatment because of loss to follow-up, the development of adverse events, or the absence of any response. Three died of HCC progression. DCV+ASV have been reported to be relatively safe even in patients with compensated cirrhosis and/or HCC.

DCV+ASV can be safely prescribed for patients with mild-to-moderate renal impairment; dose adjustments are not necessary.[@b32-gnl-12-324] However, few data are available on whether doses should be adjusted for patients with severe renal impairment/end-stage renal disease. We found that 92.3% of patients with eGFR \<50 mL/min/1.73m^2^ achieved SVR12. One patient with chronic kidney disease voluntarily discontinued treatment.

Current treatment goals for HCV patients focus on viral eradication; however, improvement of fibrosis is also important in patients treated with DAAs.[@b21-gnl-12-324] Thus, serial estimation of fibrosis status is required to predict treatment response and prognosis. Liver biopsy is an imperfect gold standard; being prone to inter-observational variation in pathologists' reports; also, the tissue samples obtained may not be representative of the entire liver. Thus, the use of noninvasive markers of fibrosis to follow-up patient treated with DAAs is considered. Previous report has shown that the LS value at the time of SVR usefully predicted liver-related events in CHC patients treated with pegIFN/RBV.[@b33-gnl-12-324] Thus, noninvasive markers should be evaluated and considered to incorporate as surveillance protocols.[@b34-gnl-12-324] However, a reduction of LS value did not always correlated with the improvement of portal hypertension.[@b35-gnl-12-324] Thus, HVPG should be monitored together with the changes of LS value.

Our study had several limitations. First, the study was retrospective, so data collection was not as strict as mandated in clinical trials. However, we collected all data prospectively using a unified in-house protocol. Second, we did not perform liver biopsy (this is the gold standard for assessment of fibrosis regression). It is ethically difficult to perform serial liver biopsies. Thus, we have no pathologic confirmation of our assessments of liver fibrosis. Thus, the exact mechanism such as the improvement of fibrosis or inflammation was hard to be confirmed. However, recent studies showed that LS values compared with FIB4/APRI was fairly reliable to predict fibrosis and treatment response in patients with chronic viral hepatitis.[@b36-gnl-12-324],[@b37-gnl-12-324] Further long-term follow-up data are needed. Lastly, for patients who have failed DCV+ASV treatment, the following treatment regimen has yet to set guidelines and is waiting for other new drugs.

In conclusion, DCV+ASV treatment was generally well tolerated in real-world clinical practice, with few discontinuations caused by the development of adverse events. Patients with CHC exhibited virological responses similar to those noted in clinical trials; and safety profile was also similar.
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![Recruitment algorithm.\
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![(A) Treatment responses at baseline, 4 weeks, end of treatment, and 12 weeks after daclatasvir+asunaprevir treatment in the entire study population; (B) SVR12 rates by prior treatment experience.\
RVR, rapid virologic response; ETR, end of treatment response; SVR12, sustained virological response at 12 weeks posttreatment.](gnl-12-324f2){#f2-gnl-12-324}

![SVR12 rates following 24 weeks of treatment with daclatasvir+asunaprevir according to age, sex, cirrhosis status, and baseline hepatitis C virus (HCV) RNA level.](gnl-12-324f3){#f3-gnl-12-324}

![Mean changes from baseline to 12 weeks posttreatment in noninvasive markers of liver fibrosis.\
LS, liver stiffness; SVR12, sustained virological response at 12 weeks posttreatment; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index.](gnl-12-324f4){#f4-gnl-12-324}

###### 

Baseline Characteristics of the Study Population (n=270)

  Variable                           Value
  ---------------------------------- ------------
  Age, yr                            60.7±12.4
   \<65                              156 (57.8)
   ≥65                               114 (42.2)
  Female sex                         163 (60.4)
  Cirrhosis                          56 (20.7)
  Body mass index, kg/m^2^           23.5±3.2
  Prior HCV therapy                  
   Treatment-naïve                   175 (64.8)
   Non-responders                    37 (13.7)
   IFN/RBV ineligible/intolerant     31 (11.5)
   Relapsers                         27 (10.0)
  HCV RNA, log10 IU/mL               5.9±0.9
  Aspartate aminotransferase, IU/L   54.3±39.1
  Alanine aminotransferase, IU/L     46.6±39.1
  Platelet count, 10^3^/μL           164.8±65.4
  Total cholesterol, mg/dL           167.3±31.3
  α-Fetoprotein, ng/mL               5.9±0.8
  Liver stiffness values, kPa        13.2±12.6
  CAP, dB/m                          228.6±38.1
  APRI score                         1.13±1.25
  FIB-4 score                        4.39±4.66

Data are presented as mean±SD or number (%).

HCV, hepatitis C virus; IFN, interferon; RBV, ribavirin; CAP, controlled attenuation parameter; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis-4.

###### 

Changes in Noninvasive Fibrosis Markers at Baseline and SVR12

                          No. of patients   Liver stiffness values   FIB-4       APRI                                                                
  ----------------------- ----------------- ------------------------ ----------- --------- ----------- ----------- --------- ----------- ----------- ---------
  Total                   270 (100)         13.2±12.8                10.5±8.8              4.57±4.78   3.03±3.08             1.40±1.36   0.60±0.54   
  Cirrhosis               56 (20.7)         25.5±17.5                19.8±11.4   \<0.001   8.76±6.23   5.19±4.98   \<0.001   2.39±1.10   1.13±0.70   \<0.001
  No cirrhosis            214 (79.3)        8.6±6.0                  6.7±3.2     \<0.001   2.87±2.55   2.34±1.66   0.001     0.97±1.23   0.38±0.23   \<0.001
  Treatment naïve         175 (64.8)        9.9±8.3                  7.7±4.7     0.001     3.49±3.21   2.41±1.59   \<0.001   1.05±0.86   0.49±0.38   \<0.001
  Treatment experienced   95 (35.2)         17.9±16.4                14.1±11.3   \<0.001   6.24±6.16   3.98±4.34   0.003     1.91±1.75   0.76±0.70   \<0.001

Data are presented as number (%) or mean±SD.

SVR, sustained virological response; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index.
